Ian Charles

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Palestine Development & Investment Co. Ltd. /Private Equity/ (PADICO-PE) is the private equity division of Palestine Development & Investment Ltd. (PSE: PADICO) founded in 1993. The firm is headquartered in Ramallah, Palestine.

Norfolk & Norwich University Hospital engages in the provision of health care services. It offers cancer care and radiotherapy, orthopaedics, plastic surgery, ophthalmology, rheumatology, children’s medicine and surgery, and specialist care for sick and premature babies. The company is headquartered in Norwich, the United Kingdom.

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

Imperial College Healthcare NHS Trust is a non-profit organization which provides community and healthcare services. It offers cardiology, endocrinology, melanoma, maternity ultrasound, maternal medicine, and major trauma center. The organization was founded on October 1, 2007 and is headquartered in London, the United Kingdom.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Part of Genus Plc, PIC Fyfield Ltd. is an investment holding British company. The company is based in Basingstoke, UK. Founded in 1884.

Part of Genus Plc, Genus Breeding Ltd. engages in genetics, reproduction and marketing of livestock. The company is based in Nantwich, UK.

Part of Genus Plc, Sygen International Ltd. is a British company that provides business support services. The company is based in Basingstoke, UK. Sygen International was founded in 1996.

Part of Genus Plc, Pig Improvement Company UK Ltd. is a company founded in 1962 by six pig farmers with the goal of making their customers the most successful pig producers in the world. The company is based in Nantwich, UK and strives to enable customers to become the most successful pork producers in the world by delivering healthy genetic improvement. PIC is committed to their customers' success and provides high-quality genetics to pig producers worldwide.

Part of Genus Plc, Fyfield (SM) Ltd. provides financial services. The company is based in Basingstoke, UK. Fyfield (SM was founded in 1971.

Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway.

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.

Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.

Part of Genus Plc, Pig Improvement Company Overseas Ltd. is an investment holding British company. The company is based in Basingstoke, UK. Pig Improvement Company Overseas was founded in 1981.

Part of Norwich BioScience Institutes, NBI Partnership Ltd. was founded in 2012 and is based in Norwich, UK. The British company provides non-scientific services to the John Innes Centre, the Earlham Institute, the Sainsbury Laboratory, and Quadram Institute Bioscience, supporting world-class research in biological sciences. The company's website includes a privacy policy and information about their services, institutes, vacancies, and a map. The website also uses cookies to improve user experience and analyze website usage.

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.

Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.